Harry Simeonidis - 18 Mar 2026 Form 4 Insider Report for INTELLIGENT BIO SOLUTIONS INC. (INBS)

Reporting relationship: Chief Executive Officer
Issuer ticker: INBS
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Mar 2026, 17:00:26 UTC
Prior SEC filing: 27 Sep 2024
Source filing: View source filing
Reporting owner signature: /s/ Harry Simeonidis

Key filing fact

Harry Simeonidis filed Form 4 for INTELLIGENT BIO SOLUTIONS INC. (INBS) on 20 Mar 2026.

Key facts

This page summarizes Harry Simeonidis's Form 4 filing for INTELLIGENT BIO SOLUTIONS INC. (INBS).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 20 Mar 2026, 17:00.

Change

Previous filing in this sequence was filed on 27 Sep 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001831767 Primary reporting owner

Simeonidis Harry

Relationship: Chief Executive Officer
Address: C/O INTELLIGENT BIO SOLUTIONS INC.,, 135 WEST 41ST STREET, 5TH FLOOR, NEW YORK
Signature: /s/ Harry Simeonidis
Signature date: 19 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INBS transaction

Common Stock

Award

Transaction value
Shares: +9,150
Change %: +226%
Price: $0.000000^*
Shares after: 13,190
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1, F2

INBS transaction

Common Stock

Award

Transaction value
Shares: +21,350
Change %: +162%
Price: $0.000000^*
Shares after: 34,540
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis.

Footnote F2

On March 18, 2026, the Issuer granted the reporting person 9,150 restricted shares of Common Stock under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan ("2019 Plan"). The awarded shares are subject to time-based vesting after 48 months and are subject to forfeiture until vested.

Footnote F3

On March 18, 2026, the Issuer granted the reporting person 21,350 restricted shares of Common Stock under the 2019 Plan. The awarded shares are subject to joint performance-based and time-based vesting requirements and are subject to forfeiture until vested.